Multiple mechanisms underlie HLA dysregulation in cervical cancer

被引:96
作者
Brady, CS
Bartholomew, JS
Burt, DJ
Duggan-Keen, MF
Glenville, S
Telford, N
Little, AM
Davidson, JA
Jimenez, P
Ruiz-Cabello, F
Garrido, F
Stern, PL
机构
[1] Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Immunol Grp, Manchester M20 4BX, Lancs, England
[2] Christie Hosp NHS Trust, Dept Cytogenet, Manchester M20 4BX, Lancs, England
[3] Royal Free Hosp, Anthony Nolan Res Inst, London NW3 2QG, England
[4] Manchester Royal Infirm, Transplantat Lab, Manchester M13 9WL, Lancs, England
[5] Univ Granada, Hosp Univ Virgen Nieves, Serv Anal Clin, Granada, Spain
来源
TISSUE ANTIGENS | 2000年 / 55卷 / 05期
关键词
cervical cancer; HPV vaccines; human papillomavirus; HLA; mutation; tumour immunotherapy;
D O I
10.1034/j.1399-0039.2000.550502.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The consistent dysregulation of HLA expression in cervical neoplasia is likely to influence the natural history of the disease and prospects for cell-mediated vaccine therapies. We have studied the underlying mechanisms in eight new cervical cancer cell lines derived from primary tumour biopsies. At least five independent mechanisms leading to changes in HLA expression were seen: HLA class I allelic transcription but no protein; abnormal HLA class I allelic transcription; no HLA-B locus transcription; loss of heterozygosity (LOH); no gamma IFN-mediated upregulation of HLA class I expression, and/or no interferon-gamma (gamma IFN)-mediated HLA class II induction. These were evident in different combinations in 7/8 cell lines showing that multiple, mostly irreversible mechanisms not overridden by gamma IFN, are responsible for HLA dysregulation in cervical neoplasia. Point mutations were responsible for lack of HLA-A2 expression in two cases. In cell line 808, the mutation encodes a stop codon in exon 3; in cell line 778, mutation of the first intron acceptor site leads to use of an alternative AG site in exon 2, resulting in a frameshift and a stop codon after the translation of only 38 amino acids. Tumour cells showing specific HLA class I loss may have selective advantage in the face of tumour-specific cytotoxic T cells (CTL). Such immune escape mechanisms present a major obstacle for the success of CTL-mediated therapies in cervical cancer.
引用
收藏
页码:401 / 411
页数:11
相关论文
共 36 条
  • [1] Cytogenetics of carcinoma of the cervix uteri: A review
    Atkin, NB
    [J]. CANCER GENETICS AND CYTOGENETICS, 1997, 95 (01) : 33 - 39
  • [2] Bai AL, 1997, J IMMUNOL, V159, P2139
  • [3] Bartholomew JS, 1997, CANCER RES, V57, P937
  • [4] BETA(2)-MICROGLOBULIN GENE-MUTATIONS - A STUDY OF ESTABLISHED COLORECTAL CELL-LINES AND FRESH TUMORS
    BICKNELL, DC
    ROWAN, A
    BODMER, WF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) : 4751 - 4755
  • [5] A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
    Borysiewicz, LK
    Fiander, A
    Nimako, M
    Man, S
    Wilkinson, GWG
    Westmoreland, D
    Evans, AS
    Adams, M
    Stacey, SN
    Boursnell, MEG
    Rutherford, E
    Hickling, JK
    Inglis, SC
    [J]. LANCET, 1996, 347 (9014) : 1523 - 1527
  • [6] Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP)
    Bunce, M
    ONeill, CM
    Barnardo, MCNM
    Krausa, P
    Browning, MJ
    Morris, PJ
    Welsh, KI
    [J]. TISSUE ANTIGENS, 1995, 46 (05): : 355 - 367
  • [7] CEREB N, 1994, J IMMUNOL, V152, P3873
  • [8] RNA surveillance - unforeseen consequences for gene expression, inherited genetic disorders and cancer
    Culbertson, MR
    [J]. TRENDS IN GENETICS, 1999, 15 (02) : 74 - 80
  • [9] DOMENA JD, 1993, TISSUE ANTIGENS, V42, P509
  • [10] Immunogenetic factors in HPV-associated cervical cancer: Influence on disease progression
    DugganKeen, MF
    Keating, PJ
    Stevens, FRA
    Sinnott, P
    Snijders, PJF
    Walboomers, JMM
    Davidson, S
    Hunter, RD
    Dyer, PA
    Stern, PL
    [J]. EUROPEAN JOURNAL OF IMMUNOGENETICS, 1996, 23 (04): : 275 - 284